REGENXBIO raises $70.5M in Series D

What does REGENXBIO do?

REGENXBIO, is a leading biotech company which develops adeno-associated viral vector based therapeutics and research tools, offering NAV, a recombinant AAV-vectorREGENX Biosciences, LLC, a biopharmaceutical company, develops therapeutics and research tools which are based on adeno associated viral vectors.

This company offers a gene delivery technology, NAV, which includes recombinant adeno associated viral vectors. This technology is used for treating metabolic disorders, hematological disorders, muscle diseases, ocular diseases and neurodegenerative disorder and clinical trails in heart failures, inherited diseases, vaccines and CNS disorders. It also offers reagent services for many applications, including molecular therapies, understanding target validation, biological activity, creating disease models and screening in vivo and genome wide association studies.

How much REGENXBIO was funded?

REGENXBIO has raised $70.5M in Series D funding on May 20, 2015 from Fidelity Biosciences, Foresite Capital, Deerfield Capital Management, Sectoral Asset Management, Cormorant Asset Management and Tourbillon Global Ventures.

Previous funding

• $7.9M in Venture round on November 7, 2013
• $30M in Series C round on January 21, 2015 from Fidelity Biosciences, Brookside Capital, Deerfield Capital Management and Venrock

What is next for REGENXBIO?

REGENXBIO, has raised a total of $110M in investments to date.  With this financing, the company is well positioned to support its lead programs into initial clinical studies and for establishing many new clinical candidate for growing its pipeline of NAV Technology based treatment. The company plans to use the funding to advance its lead programs through clinical development, build the clinical and manufacturing infrastructure and for expanding its team.

More about REGENXBIO

REGENXBIO, was founded in 2009 and has its headquarters in Washington, DC. The REGENXBIO’S NAV Technology has marked a new era of gene therapy innovation.  It is collaborating with the world class clinical advisors to advance the development of the life altering gene therapy treatment for ocular diseases and lysosomal storage disorders.